GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Allurion Technologies Inc (NYSE:ALUR) » Definitions » Shares Outstanding (EOP)

Allurion Technologies (Allurion Technologies) Shares Outstanding (EOP) : 47.69 Mil (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Allurion Technologies Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Allurion Technologies's shares outstanding for the quarter that ended in Dec. 2023 was 47.69 Mil.

Allurion Technologies's quarterly shares outstanding increased from Sep. 2023 (47.46 Mil) to Dec. 2023 (47.69 Mil). It means Allurion Technologies issued new shares from Sep. 2023 to Dec. 2023 .

Allurion Technologies's annual shares outstanding increased from Dec. 2022 (46.50 Mil) to Dec. 2023 (47.69 Mil). It means Allurion Technologies issued new shares from Dec. 2022 to Dec. 2023 .


Allurion Technologies Shares Outstanding (EOP) Historical Data

The historical data trend for Allurion Technologies's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allurion Technologies Shares Outstanding (EOP) Chart

Allurion Technologies Annual Data
Trend Dec21 Dec22 Dec23
Shares Outstanding (EOP)
46.50 46.50 47.69

Allurion Technologies Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only 46.50 46.50 46.50 47.46 47.69

Competitive Comparison of Allurion Technologies's Shares Outstanding (EOP)

For the Medical Devices subindustry, Allurion Technologies's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allurion Technologies's Shares Outstanding (EOP) Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Allurion Technologies's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Allurion Technologies's Shares Outstanding (EOP) falls into.



Allurion Technologies Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Allurion Technologies  (NYSE:ALUR) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Allurion Technologies Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Allurion Technologies's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Allurion Technologies (Allurion Technologies) Business Description

Traded in Other Exchanges
N/A
Address
11 Huron Drive, Natick, MA, USA, 01760
Website
Allurion Technologies Inc is a leading medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
Executives
Omar Ishrak director 710 MEDTRONIC PKWY, MS LC300, MINNEAPOLIS MN 55432
Nicholas Sheridan Lewin director 3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Krishna K. Gupta director, 10 percent owner 307 HARVARD ST, CAMBRIDGE MA 02139
Christopher J Geberth officer: Chief Financial Officer 11 HURON DRIVE, SUITE 200, NATICK MA 01760
Michael R Davin director C/O CYNOSURE, INC., 5 CARLISLE ROAD, WESTFORD MA 01886
Larson Douglas Hudson director 11 HURON DRIVE, SUITE 200, NATICK MA 01760
Benoit Chardon officer: Chief Commercial Officer 11 HURON DRIVE, SUITE 200, NATICK MA 01760
Shantanu Gaur director, officer: Chief Executive Officer 11 HURON DRIVE, SUITE 200, NATICK MA 01760
Ram Chuttani officer: Chief Medical Officer 11 HURON DRIVE, SUITE 200, NATICK MA 01760